Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Our e-services for applications, projects and assessments (the eServices portal) close on Thursday 26 January at 4:30pm because of system upgrades. We expect to open them again on Friday 27 January at 8am the latest.

Life Science Research and Development in the United States of America

An overview from the federal perspective

Book cover Life Science Research and Development in the United States of America
Published
2009-June
Series number
VA 2009:15
Publisher
Vinnova
Author
Eva Hunnius Ohlin & Martin A. Wikström - ITPS Washington D.C.
ISBN
978-91-85959-64-8
ISSN
1650-3104/1651-355X
Number of pages
120

In December 2006, Vinnova was assigned by the Swedish government to conduct an international benchmarking of the Swedish sectorial innovation systems in pharmaceuticals, biotechnology and medical technology. Case studies and international comparisons of activities in different countries are important in assessing and understanding the Swedish conditions for life science research and innovation. The by far most influential country globally is the United States considering the size of the science base, R&Dinvestments and industry. The trends in the U.S. therefore tend to have a strong influence on the global development. Vinnova has thus commissioned ITPS (today the Swedish Agency for Growth Policy Analysis) to analyse and describe the situation for a number of life science areas in the U.S.

This study which is one of the above mentioned studies is based on data and information concerning primarily policy trends in the U.S. Life Science research and innovation system. The U.S. research-funding situation as well U.S. life science R&D in relation to the rest of the world is thus described as well as the large heterogeneity within the U.S. in terms of R&D intensity between states. Major federal funding agencies of R&D in the life sciences are described, their funding levels, as well as some of their prioritized areas. How agencies work to stimulate innovation at universities is also discussed. The attitude to international collaborations from the White House and agencies, in particular the NIH, is of special interest as is the impact of the new Administration.

This publication is based on published studies and information, searches in databases, interviews as well as analysis of the gathered materials.

Last updated 15 December 2022

Page statistics